Your browser doesn't support javascript.
loading
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno, Carol; Greil, Richard; Demirkan, Fatih; Tedeschi, Alessandra; Anz, Bertrand; Larratt, Loree; Simkovic, Martin; Samoilova, Olga; Novak, Jan; Ben-Yehuda, Dina; Strugov, Vladimir; Gill, Devinder; Gribben, John G; Hsu, Emily; Lih, Chih-Jian; Zhou, Cathy; Clow, Fong; James, Danelle F; Styles, Lori; Flinn, Ian W.
Afiliación
  • Moreno C; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain. Electronic address: cmorenoa@santpau.cat.
  • Greil R; Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Salzburg, Austria.
  • Demirkan F; Dokuz Eylul University, Izmir, Turkey.
  • Tedeschi A; ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Anz B; Tennessee Oncology, Chattanooga, TN, USA.
  • Larratt L; University of Alberta, Edmonton, AB, Canada.
  • Simkovic M; University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
  • Samoilova O; Nizhny Novogorod Regional Clinical Hospital, Nizhny Novogorod, Russia.
  • Novak J; University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Ben-Yehuda D; Department of Hematology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
  • Strugov V; Almazov National Medical Research Centre, St Petersburg, Russia.
  • Gill D; Princess Alexandra Hospital, Brisbane, QLD, Australia.
  • Gribben JG; Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Hsu E; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • Lih CJ; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • Zhou C; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • Clow F; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • James DF; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • Styles L; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • Flinn IW; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
Lancet Oncol ; 20(1): 43-56, 2019 01.
Article en En | MEDLINE | ID: mdl-30522969
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Clorambucilo / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Clorambucilo / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido